Internet Archive Scholar

Referee report. For: Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C [version 1; peer review: 2 approved]

Salvador Soriano
2022

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.4 MB)
https://web.archive.org/web/20220612061823/https://d212y8ha88k086.cloudfront.net/manuscripts/18754/17baf779-0dac-4cb4-a52b-1489dbc3382d_16986_-_isabelle_williams.pdf?doi=10.12688/wellcomeopenres.16986.1&numberOfBrowsableCollections=9&numberOfBrowsableInstitutionalCollections=0&numberOfBrowsableGateways=14

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Blockade of tumour necrosis factor (anti-TNF) is effective in patients with Crohn's Disease but has been associated with infection risk and neurological complications such as demyelination. Niemann-Pick disease Type C1 (NPC1) is a lysosomal storage disorder presenting in childhood with neurological deterioration, liver damage and respiratory infections. Some NPC1 patients develop severe Crohn's disease. Our objective was to investigate the safety and effectiveness of anti-TNF in NPC1 patients
more » ... th Crohn's disease. Methods: Retrospective data on phenotype and therapy response were collected in 2019-2020 for the time period 2014 to 2020 from patients in the UK, France, Germany and Canada with genetically confirmed NPC1 defects and intestinal inflammation. We investigated TNF secretion in peripheral blood mononuclear cells treated with NPC1 inhibitor in response to bacterial stimuli.
doi:10.21956/wellcomeopenres.18754.r50669 fatcat:vycgxqhjyfckxnvzcy56gr7z3y
Citation

Salvador Soriano. "Referee report. For: Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C [version 1; peer review: 2 approved]." (2022)